JP2023533003A5 - - Google Patents

Info

Publication number
JP2023533003A5
JP2023533003A5 JP2023500425A JP2023500425A JP2023533003A5 JP 2023533003 A5 JP2023533003 A5 JP 2023533003A5 JP 2023500425 A JP2023500425 A JP 2023500425A JP 2023500425 A JP2023500425 A JP 2023500425A JP 2023533003 A5 JP2023533003 A5 JP 2023533003A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
pharmaceutically acceptable
isomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023500425A
Other languages
English (en)
Japanese (ja)
Other versions
JP7712703B2 (ja
JP2023533003A (ja
Filing date
Publication date
Priority claimed from CN202010633550.2A external-priority patent/CN113896711A/zh
Application filed filed Critical
Publication of JP2023533003A publication Critical patent/JP2023533003A/ja
Publication of JP2023533003A5 publication Critical patent/JP2023533003A5/ja
Application granted granted Critical
Publication of JP7712703B2 publication Critical patent/JP7712703B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023500425A 2020-07-06 2021-06-28 ヘテロ環式免疫調節物質 Active JP7712703B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010633550.2 2020-07-06
CN202010633550.2A CN113896711A (zh) 2020-07-06 2020-07-06 杂环类免疫调节剂
PCT/CN2021/102873 WO2022007659A1 (zh) 2020-07-06 2021-06-28 杂环类免疫调节剂

Publications (3)

Publication Number Publication Date
JP2023533003A JP2023533003A (ja) 2023-08-01
JP2023533003A5 true JP2023533003A5 (https=) 2024-05-14
JP7712703B2 JP7712703B2 (ja) 2025-07-24

Family

ID=79186707

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500425A Active JP7712703B2 (ja) 2020-07-06 2021-06-28 ヘテロ環式免疫調節物質

Country Status (9)

Country Link
US (1) US20230271933A1 (https=)
EP (1) EP4177247A4 (https=)
JP (1) JP7712703B2 (https=)
KR (1) KR20230037035A (https=)
CN (2) CN113896711A (https=)
AU (1) AU2021303635A1 (https=)
CA (1) CA3189041A1 (https=)
MX (1) MX2023000382A (https=)
WO (1) WO2022007659A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
CN120813578A (zh) * 2023-04-28 2025-10-17 北京诺诚健华医药科技有限公司 杂环类gspt1降解剂
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025195464A1 (zh) * 2024-03-21 2025-09-25 上海惠康济民生物医药技术有限公司 取代的异吲哚啉类化合物、制备方法、药物组合物及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3202460T3 (pl) * 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
CA3108974C (en) 2012-08-09 2023-04-04 Celgene Corporation Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
WO2014116573A1 (en) * 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
ES2963446T3 (es) * 2015-09-29 2024-03-27 Kangpu Biopharmaceuticals Ltd Composición farmacéutica y aplicación de la misma
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
WO2018140671A1 (en) * 2017-01-27 2018-08-02 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
EP4467143B1 (en) * 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
AU2018351050B2 (en) * 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
CN107739389B (zh) 2017-11-03 2020-03-31 华东师范大学 3位取代的(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮类化合物及其合成方法
KR102718800B1 (ko) * 2018-05-23 2024-10-18 셀진 코포레이션 다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도
CA3106239A1 (en) * 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
WO2020210630A1 (en) * 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos

Similar Documents

Publication Publication Date Title
JP2023533003A5 (https=)
JP2025510656A5 (https=)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2007105350A (ru) 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы
JP2020521740A5 (https=)
JP2020504715A5 (https=)
IL292608A (en) History of pyridine-2(1h)-one quinolinone as mutant dehydrogenase inhibitors-isocitrate
JP2014513110A5 (https=)
JP2016525135A5 (https=)
JP2005534669A5 (https=)
JP2023533203A5 (https=)
JP2021514001A5 (https=)
JP2022553376A5 (https=)
JP2020514311A5 (https=)
JP2015533177A5 (https=)
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
JP2008509949A5 (https=)
JP2016520131A5 (https=)
JP2013519704A5 (https=)
JP2020506895A5 (https=)
JP2023531709A5 (https=)
JP2022534704A5 (https=)
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
JP2020520925A5 (https=)